CELU vs. ELDN, ALTS, EDIT, ACTU, SLS, LFVN, SPRO, ACRS, DERM, and ENTA
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Eledon Pharmaceuticals (ELDN), Janone (ALTS), Editas Medicine (EDIT), Actuate Therapeutics (ACTU), SELLAS Life Sciences Group (SLS), LifeVantage (LFVN), Spero Therapeutics (SPRO), Aclaris Therapeutics (ACRS), Journey Medical (DERM), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry.
Celularity vs. Its Competitors
Celularity (NASDAQ:CELU) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
Eledon Pharmaceuticals has a consensus price target of $9.00, suggesting a potential upside of 230.28%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Celularity.
In the previous week, Eledon Pharmaceuticals had 10 more articles in the media than Celularity. MarketBeat recorded 10 mentions for Eledon Pharmaceuticals and 0 mentions for Celularity. Eledon Pharmaceuticals' average media sentiment score of 1.17 beat Celularity's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.
Celularity has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.
Eledon Pharmaceuticals has lower revenue, but higher earnings than Celularity. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Eledon Pharmaceuticals' return on equity of -79.54% beat Celularity's return on equity.
19.0% of Celularity shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 22.1% of Celularity shares are owned by company insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Eledon Pharmaceuticals received 21 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 70.73% of users gave Eledon Pharmaceuticals an outperform vote while only 40.00% of users gave Celularity an outperform vote.
Summary
Eledon Pharmaceuticals beats Celularity on 13 of the 17 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
This page (NASDAQ:CELU) was last updated on 6/25/2025 by MarketBeat.com Staff
Buy CELU Stock Free CELU Stock Alerts